June 19, 2026
7 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .
Compounded medications currently represent an estimated 1% to 3% of all prescriptions written in the United States, according to a recent 2025-2026 report issued by the Alliance for Pharmacy Compounding.“There’s a good chance you know someone who has benefited — or whose pet has benefited — from a compounded drug,” read the report, which was released in March.
Compounded drugs (1-3% prescriptions) bypass FDA oversight to address gaps but require physician due diligence on pharmacy vetting and safety. Health-tech signal: demand for verified-pharmacy APIs and compliance platforms in the unregulated compounding sector.
June 19, 2026
7 min read
Add topic to email alerts
Receive an email when new articles are posted on
Please provide your email address to receive an email when new articles are posted on .

FDA warns telehealth companies over compounded GLP-1s

How lab data powers precision commercialization to drive therapy adoption

Pharmalittle: We're reading about Pfizer's emergency penicillin program, a Sanofi diabetes drug, and more

Why one health system invested in its PBM as GLP-1 costs surged

Opinion | The Refill Encounter: Managing Medications the Modern Way

From the rarest conditions to the pandemics that affect societal norms, infections are abundant in everyday life.Although some…

Direct-to-consumer pharmacies could offer substantial savings for patients taking generic medications, according to experts. …

The FDA has issued a new batch of warning letters to 25 telehealth companies, accusing them of making false and misleading claims…

If that proposal is finalized, the exclusion would likely limit the mass compounding of those medicines unless they appear on…

Persistent and prolonged drug shortages across the country are affecting delivery of care across well over 100 therapeutic areas,…

In this Diabetes in Real Life column, Susan Weiner, MS, RDN, CDN, CDCES, FADCES, talks with Susan Cornell, PharmD, CDCES, FAPhA,…